A methodological framework to enhance the clinical success of cancer immunotherapy

被引：47

作者：

Hoos, Axel ^{[1
,2
]}

Britten, Cedrik M. ^{[3
,4
,5
]}

Huber, Christoph ^{[5
,6
]}

O'Donnell-Tormey, Jill ^{[2
]}

机构：

[1] Bristol Myers Squibb Co, Wallingford, CT 06492 USA

[2] Canc Res Inst, Canc Immunotherapy Consortium, New York, NY USA

[3] Johannes Gutenberg Univ Mainz, Dept Med, Univ Med Ctr, Mainz, Germany

[4] Ribological GmbH, Mainz, Germany

[5] Assoc Canc Immunotherapy CIMT, Mainz, Germany

[6] Ctr Translat Oncol & Immunol TRON, Mainz, Germany

来源：

NATURE BIOTECHNOLOGY | 2011年 / 29卷 / 10期

关键词：

VACCINE-CONSORTIUM; HARMONIZATION GUIDELINES; PARADIGM; ASSAYS;

D O I：

10.1038/nbt.2000

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

引用

页码：867 / 870

页数：4

共 19 条

[1]

[Anonymous], 2009, GUID IND CLIN CONS T

[2] Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium [J].

Britten, Cedrik Michael ;

Janetzki, Sylvia ;

Ben-Porat, Leah ;

Clay, Timothy M. ;

Kalos, Michael ;

Maecker, Holden ;

Odunsi, Kunle ;

Pride, Michael ;

Old, Lloyd ;

Hoos, Axel ;

Romero, Pedro .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2009, 58 (10) :1701-1713

[3]

European Medicines Agency, 2010, EMACHMPEWP4334782010

[4] Lessons from randomized phase III studies with active cancer immunotherapies - Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC) [J].

Finke, Lothar H. ;

Wentworth, Kerry ;

Blumenstein, Brent ;

Rudolph, Natalie S. ;

Levitsky, Hyarn ;

Hoos, Axel .

VACCINE, 2007, 25 :B97-B109

[5] Molecular origins of cancer - Cancer immunology [J].

Finn, Olivera J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (25) :2704-2715

[6] The cancer vaccine roller coaster [J].

Goldman, Bruce ;

DeFrancesco, Laura .

NATURE BIOTECHNOLOGY, 2009, 27 (02) :129-139

[7] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[8] A clinical development paradigm for cancer vaccines and related biologics [J].

Hoos, Axel ;

Parmiani, Giorgio ;

Hege, Kristen ;

Sznol, Mario ;

Loibner, Hans ;

Eggermont, Alexander ;

Urba, Walter ;

Blumenstein, Brent ;

Sacks, Natalie ;

Keilholz, Ulrich ;

Nichol, Geoffrey .

JOURNAL OF IMMUNOTHERAPY, 2007, 30 (01) :1-15

[9] Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy [J].

Hoos, Axel ;

Ibrahim, Ramy ;

Korman, Alan ;

Abdallah, Kald ;

Berman, David ;

Shahabi, Vafa ;

Chin, Kevin ;

Canetta, Renzo ;

Humphrey, Rachel .

SEMINARS IN ONCOLOGY, 2010, 37 (05) :533-546

[10] Improved Endpoints for Cancer Immunotherapy Trials [J].

Hoos, Axel ;

Eggermont, Alexander M. M. ;

Janetzki, Sylvia ;

Hodi, F. Stephen ;

Ibrahim, Ramy ;

Anderson, Aparna ;

Humphrey, Rachel ;

Blumenstein, Brent ;

Old, Lloyd ;

Wolchok, Jedd .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2010, 102 (18) :1388-1397

← 1 2 →